SCHEMBL22769714

SCHEMBL22769714

CC1(C)CCN(CCCOc2cc3nccc(Oc4ccc(N(C(=O)C5(C(N)=O)CC5)c5ccc(F)cc5)cc4F)c3c3c2OCCO3)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 8/20 0.51
KDR P35968 7/20 0.50
RET P07949 6/20 0.49
RAF1 P04049 2/20 0.47
BRAF P15056 2/20 0.47
PLK4 O00444 1/20 0.47
STK25 O00506 1/20 0.47
CIT O14578 1/20 0.47
AURKA O14965 1/20 0.47
CHUK O15111 1/20 0.47
MUSK O15146 1/20 0.47
EPHB6 O15197 1/20 0.47
MAPK13 O15264 1/20 0.47
MAP3K13 O43283 1/20 0.47
DAPK3 O43293 1/20 0.47
MAP3K7 O43318 1/20 0.47
RIPK2 O43353 1/20 0.47
JAK2 O60674 1/20 0.47
ROCK2 O75116 1/20 0.47
PAK3 O75914 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22769700 0.96 MET (0.51) METKDRRETRAF1BRAF
SCHEMBL22769728 0.95 MET (0.50) METKDRRETRAF1BRAF
SCHEMBL22769729 0.94 MET (0.51) METKDRRETRAF1BRAF
SCHEMBL22801673 0.94 KDR (0.52) METKDRRETRAF1BRAF
SCHEMBL21246963 0.94 KDR (0.51) METKDRRETRAF1BRAF
SCHEMBL22769705 0.94 KDR (0.57) METKDRRETRAF1BRAF
SCHEMBL22769723 0.92 KDR (0.49) METKDRRETRAF1BRAF
SCHEMBL22769724 0.89 MET (0.55) METKDRRETRAF1BRAF
SCHEMBL22769703 0.89 MET (0.51) METKDRRETRAF1BRAF
SCHEMBL22769704 0.89 MET (0.55) METKDRRETRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3750893-B1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-04-19 EP disclosed
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2022-08-09 US disclosed
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2020-12-24 US disclosed
EP-3750893-A1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2020-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof KDR, MET, ABL1 MET 2/4885KDR 1/4885RET 7/4885
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF KDR, MET, ABL1 MET 2/4885KDR 1/4885RET 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.